Your Gut May Be Making A Molecule That Raises Alzheimer’s Risk

TL;DR

Prime Big Deal Days · Oct 6–7Offer from Amazon

Get health and wellness essentials delivered free — and shop member deals

• Fast, free delivery on millions of items
• Access to Prime Big Deal Days deals on October 6–7
• Prime Video, Amazon Music and more included

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

A study published in Nature Communications links higher blood levels of imidazole propionate, a molecule produced by some gut bacteria, with Alzheimer’s-related biological markers and faster cognitive decline. Mouse experiments found effects on amyloid and tau, but the human findings show an association, not proof that ImP causes Alzheimer’s or that lowering it prevents disease.

Researchers report that imidazole propionate (ImP), a molecule produced by some gut bacteria, may affect brain changes associated with Alzheimer’s disease. In a study published in Nature Communications, mouse experiments linked ImP exposure to increased accumulation of amyloid and tau, while blood measurements from nearly 1,200 people associated higher ImP levels with Alzheimer’s-related markers and faster cognitive decline.

The team, led by University of Wisconsin-Madison researchers Barbara Bendlin and Federico Rey, examined how a compound made in the digestive system might relate to changes in the brain. Some gut bacteria produce ImP while using histidine, an amino acid found in many foods. The amount produced appears to vary widely between people, and ImP-producing bacteria are present in many people without being abundant in most, Rey said.

In mice, the researchers found that ImP could reach the brain and was associated with greater accumulation of beta-amyloid and tau, proteins linked to Alzheimer’s disease. The researchers described the findings as evidence that the compound may contribute to disease-related changes; the experiment does not establish that the same process causes Alzheimer’s in people.

For the human part of the study, the team analyzed blood samples from almost 1,200 participants in the Wisconsin Registry for Alzheimer’s Prevention and studies through the Wisconsin Alzheimer’s Disease Research Center. People with higher blood ImP concentrations were more likely to have biological markers associated with abnormal proteins and impaired neuron function. Participants’ repeated cognitive test results also showed that those with the highest ImP levels experienced faster decline, according to Rey. These observations establish a link, but cannot by themselves show that ImP caused the decline.

A Potential Target Beyond Diet

The findings identify a possible connection between gut bacteria and Alzheimer’s-related changes that researchers can investigate more directly. If further work confirms that ImP contributes to disease processes, reducing the molecule itself might offer a target for prevention or treatment. That possibility matters because the study points to a measurable blood compound and a biological pathway, rather than treating the gut microbiome as a single, undifferentiated factor.

The researchers caution against interpreting the result as a reason to cut particular foods. ImP-producing bacteria generate the molecule from histidine, an amino acid that the body needs and that occurs across many foods, especially protein-rich ones. Bendlin said broad dietary improvement may be helpful, but eliminating a food such as eggs or red meat would not be a straightforward way to control ImP. The proposed direction is research into approaches that lower ImP in the bloodstream, not a current dietary prescription or proven treatment.

The potential relevance may extend beyond Alzheimer’s. Earlier studies have linked ImP with type 2 diabetes and coronary artery disease, according to the report. Whether those links share a mechanism, and whether changing ImP would affect any of these conditions, remains to be established.

From Gut Differences to ImP

The study follows earlier work by Bendlin and Rey’s team comparing gut microorganisms in people with Alzheimer’s and healthy individuals. The researchers have spent years investigating whether differences in those microbial communities could relate to brain changes. The current report narrows that question to imidazole propionate, a compound that can enter the circulation after it is produced in the gut.

The researchers also identified a genetic variation associated with substantially higher ImP levels in the bloodstream. About 43% of participants in the study carried the variation. The team suspects it could affect how efficiently the kidneys clear ImP, but that explanation is not confirmed by the reported finding. Rey noted that the variation had previously been associated with Alzheimer’s risk in large genetic studies; the new work offers a possible connection, rather than proof of why that association exists.

Researchers from the University of California, Los Angeles, and the University of Gothenburg also contributed. The work received support from the Wisconsin Partnership Program, the National Institutes of Health and the U.S. Department of Agriculture.

“Since then, we’ve been trying to figure out how this difference in the gut perhaps leads to changes in the brain.”

— Barbara Bendlin, University of Wisconsin-Madison professor of medicine

Cause and Treatment Remain Unproven

The human results show that higher ImP levels occur alongside disease-related markers and faster cognitive decline; they do not prove that ImP causes either outcome. The mouse findings add experimental evidence of effects on amyloid and tau, but whether those results predict what happens in people is not yet clear. The report does not establish how much ImP would need to be reduced to change risk, or whether lowering it would slow decline.

The proposed kidney explanation for the genetic association also remains a hypothesis. The study summary does not specify an intervention trial showing that a drug or dietary change can safely lower ImP or improve Alzheimer’s outcomes. It is also unclear whether ImP has the same relevance across different forms of dementia or among people with different underlying risk factors.

Testing Ways to Lower ImP

The next step is to test whether ImP plays a causal role and whether reducing blood levels changes Alzheimer’s-related outcomes. Researchers may investigate how gut bacteria produce the molecule, how the body clears it, and how the identified genetic variation affects those processes. The team’s proposed direction is to seek an ImP-lowering inhibitor and assess whether it can reduce biological risk markers or cognitive decline in future studies.

Until those studies are done, ImP should be treated as a research lead rather than a clinical target. The report provides no basis for people to avoid histidine-rich foods or to change medical care. Further research will need to clarify whether the association holds in other groups and whether an intervention can produce a meaningful benefit.

Key Questions

What is imidazole propionate?

Imidazole propionate (ImP) is a compound produced by certain gut bacteria as they use histidine, an amino acid. It can enter the bloodstream after being made in the digestive system.

Does this study prove that ImP causes Alzheimer’s disease?

No. The mouse experiments linked ImP with increased amyloid and tau accumulation, and the human data linked higher blood levels with disease-related markers and faster cognitive decline. The human findings are observational and do not prove that ImP causes Alzheimer’s.

Should people avoid foods that contain histidine?

The researchers did not recommend avoiding specific foods. Histidine is an essential amino acid found in many foods, and the report says reducing ImP through diet may not be simple. The study does not provide a dietary treatment plan.

Could lowering ImP prevent or slow Alzheimer’s?

That is a possibility researchers want to test, not a demonstrated effect. The study did not show that an ImP-lowering drug or diet prevents Alzheimer’s or slows cognitive decline in people.

Source: rss